Abstract
ABSTRACTIn treating and managing acute psychosis in patients with schizophrenia, early intervention may be valuable. The need to quickly control severe symptoms, however, must be balanced with a treatment algorithm that is both safe and effective. The present management of acute psychotic agitation varies among clinicians. Key treatment goals have been to calm the agitated, assaultive, violent, or disruptive patient, minimize the danger to self and others, and achieve a smooth transition from intramuscular to oral maintenance. For many years, intramuscular treatment with benzodiazepines and/or conventional antipsychotics, such as haloperidol, has been the mainstay of treatment for acute psychosis. Unfortunately, the poor tolerability of conventional antipsychotics compromises their usefulness for both short- and long-term treatment. Although new antipsychotics have a more favorable side-effect profile, the transition from an intramuscular formulation has been problematic. Fortunately, the development of intramuscular formulations of olanzapine and ziprasidone offer new treatment options for patients experiencing acute psychotic episodes. This article will review the use of intramuscular agents, standard antipsychotics, and new antipsychotics in the emergency room setting. The strengths and limitations of each will be discussed.
Publisher
Cambridge University Press (CUP)
Subject
Psychiatry and Mental health,Clinical Neurology
Reference30 articles.
1. Kinon BJ . Presented at: US Psych Congress; November 16-29, 2000; San Diego, Calif.
2. Risperdal [package insert]. Titusville, NJ: Janssen Pharmaceutica Products, L.P.; 2003.
3. Possible interaction between clozapine and lorazepam;Cobb;Am J Psychiatry,1991
4. Intramuscular Ziprasidone Compared With Intramuscular Haloperidol in the Treatment of Acute Psychosis
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献